**ASX Announcement**

**16 November 2026**

# OncoSil Medical to Present at the Bell Potter Healthcare Conference 2026

**Sydney, Australia – 16 November 2026:** OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC) and distal cholangiocarcinoma (dCCA), is pleased to advise that it will present at the Bell Potter Healthcare Conference 2026 on **Thursday, 19 November 2026, at 12:30 pm AEDT**.

Mr Nigel Lange, CEO & Managing Director will present and provide an update on OncoSil Medical's business, growth strategy and upcoming catalysts.

Hosted by Bell Potter, the virtual conference will run from 17 to 19 November 2026 and will feature presentations from 48 ASX-listed healthcare companies across the biotechnology, medical device, healthcare software and diagnostics sectors.

**Presentation Details**

| | |
|---|---|
| **Date:** | **Thursday, 19 November 2026** |
| **Time:** | **12:30 pm AEDT (Session 2)** |
| **Presenter:** | **Mr Nigel Lange, CEO & Managing Director** |
| **Format:** | **Virtual via Bell Potter Client Access** |

**How to View the Conference**

The virtual conference will be exclusively available to live-stream on Bell Potter Client Access. Investors can view the presentation by logging in to Client Access and selecting the Healthcare Conference 2026 tab in the top navigation.

Investors without a Client Access account can register prior to the conference or ask their Bell Potter adviser to set up an account. For assistance, contact your Bell Potter adviser or call 1300 0 BELLS (23557).

Further information, including the conference schedule, is available on the Bell Potter website.

Click **here** to view this announcement on Investor Hub.

**Authorisation & Additional Information**

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

## For further information, please contact:

| | |
|---|---|
| **Mr. Nigel Lange**<br>CEO & Managing Director<br>E: nigel.lange@oncosil.com<br>T: +49 160 9642 4981 | **Mr. Tim Luscombe & Ms. Nova Taylor**<br>Joint Company Secretaries<br>E: tim.luscombe@bio101.com & nova.taylor@bio101.com<br>T: +61 429 707 079 & +61 414 877 703 |

**About OncoSil Medical**

OncoSil Medical (ASX) is a global medical device company focused on Interventional Oncology, with a mission to improve outcomes for people living with cancer. The company has developed OncoSil™, a single-use brachytherapy (internal radiation) device that delivers a pre-determined dose of beta radiation directly into cancerous tissue using targeted intratumoural placement of Phosphorous-32 ($^{32}P$) Microparticles. Its targeted approach enables a greater radiation dose to be delivered directly to the tumour while limiting exposure to surrounding critical organs.

In the United States, OncoSil™ is indicated for the treatment of patients with distal cholangiocarcinoma (dCCA) that is both unresectable (locally advanced and/or unfit for surgery) and non-metastatic, as an adjunct to systemic therapy. In markets outside the United States where OncoSil™ has received regulatory approval, OncoSil™ is indicated for the treatment of patients with unresectable locally advanced pancreatic cancer, in addition to gemcitabine-based chemotherapy.

Pancreatic cancer is the 12$^{th}$ most common cancer in men and the 11$^{th}$ most common cancer in women across the globe, with 500,000 new cases detected every year[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival. Distal cholangiocarcinoma (dCCA) is a rare form of bile duct cancer. It is often diagnosed at an advanced stage, when surgical treatment may no longer be possible, and is associated with a poor prognosis.

OncoSil™ has received CE Marking approval, providing marketing authorisation in the European Union and the United Kingdom. OncoSil™ has also received approval from the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE) for the treatment of patients with unresectable, non-metastatic distal cholangiocarcinoma (dCCA), as an adjunct to systemic therapy. OncoSil™ has been designated as a Breakthrough Device in Europe and the United States. It is currently approved for sale in 30+ countries, including the European Union, United Kingdom, United States, Australia, Saudi Arabia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

[1] https://gco.iarc.fr/en